Skip to content

Safety and efficacy of cranial bone transport technique for ischemic stroke: an exploratory randomized controlled clinical trail

Safety and efficacy of cranial bone transport technique for ischemic stroke: an exploratory randomized controlled clinical trail

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116964
Enrollment
Unknown
Registered
2026-01-17
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Trial Group :Cranioplasty with micro-movement + conventional medical therapy. Preoperative preparation begins on day 1 after randomization
craniotomy is performed on day 2 after randomization. Cranioplasty micro-movement begins on postoperative day 4: upward micro-movement for 3 days (1 mm/day), followed by downward micro-movement for 3

Sponsors

The First Hospital of Jilin University.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years, regardless of gender; 2. Patients with clinically confirmed ischemic stroke within 14 days of onset and a pre-randomization mRS score >=4; 3. Patients with imaging-confirmed anterior circulation cerebral infarction; 4. Patients or their legal representatives consent to this treatment and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing mechanical thrombectomy after symptom onset; 2. Patients who underwent intracranial surgery within the past 6 months; 3. Patients with atrial fibrillation; 4. Patients with significant intracranial hypertension, such as cerebral edema or hydrocephalus; 5. Patients with a history of intracranial or scalp infection within the past year; 6. Severe consciousness impairment: NIHSS consciousness level score > 1 point; 7. Patients with skull defects; 8. Patients with concomitant major organ failure, tumors, or undergoing antineoplastic therapy; 9. Pregnant or lactating women; 10. Patients with severe psychiatric disorders or other conditions preventing cooperation with data collection; 11. Participation in another clinical trial within 30 days prior to randomization, or current participation in another clinical trial; 12. Other circumstances deemed inappropriate for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
The proportion of patients with an mRS score of 0-2 at 90 days after randomization;

Secondary

MeasureTime frame
The proportion of patients with an mRS score of 0-2 at 30 days after randomization;The proportion of patients with an mRS score of 0-1 at 90 days after randomization;The distribution of mRS scores at 90 days after randomization;The NIHSS scores between the two groups at 14 days/at discharge after randomization;

Countries

China

Contacts

Public ContactYang Yi

The First Hospital of Jilin University

zhen1ni2@163.com+86 431 8878 2378

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026